Increased Radiation Pneumonitis after Crizotinib and Concurrent Thoracic Radiotherapy in Patients with ALK-positive Non-small-cell Lung Cancer
Volume: 105, Issue: 1, Pages: S148 - S149
Published: Sep 1, 2019
Abstract
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) and its administration has achieved considerable success. Preclinical studies have demonstrated crizotinib in combination with radiation could enhance the inhibitory effect on ALK-positive NSCLC. Radiation pneumonitis is a dose limiting toxicity of...
Paper Details
Title
Increased Radiation Pneumonitis after Crizotinib and Concurrent Thoracic Radiotherapy in Patients with ALK-positive Non-small-cell Lung Cancer
Published Date
Sep 1, 2019
Volume
105
Issue
1
Pages
S148 - S149
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History